We investigated the therapeutic potential of apoE-derived peptide, 6KApoEp that blocks the interaction of apoE with N-terminal APP for modifying AD-like pathology in APP/PS1 mice that express each apoE isoform of apoE2, apoE3, or apoE4. This evidence concerns the gene APOE and Alzheimer disease.